Abstract:
Die vorliegende Erfindung betrifft neue Gemische von (Meth)acrylester von polyalkoxyliertem Trimethylolpropan der Formel (I) mit AO bedeutet für jedes AO unabhängig voneinander EO, PO oder BO wobei EO bedeutet O-CH2-CH2-PO bedeutet unabhängig voneinander O-CH2-CH(CH3)- oder 0-CH(CH3)-CH2-BO bedeutet unabhängig voneinander O-CH2-CH(CH2-CH3)- oder O-CH(CH2-CH3)-CH2-pl + p2 + p3 ist 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 oder 75, Rl, R2, R3 unabhängig voneinander H oder CH3, ein vereinfachtes Verfahren zur Herstellung dieser Estergemische und Verwendung der so erhältlichen Reaktionsgemische.
Abstract:
Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.
Abstract:
Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.
Abstract:
The invention relates to novel methods of preventing, treating, or ameliorating Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis and Crohn's disease, by administering compounds that are capable of inhibiting human neutrophil elastase (HNE), as well as to the use of said compounds for preparing pharmaceutical compositions for preventing, treating, or ameliorating IBD. Furthermore, the invention relates to pharmaceutical compositions comprising HNE inhibitors and further comprising one or more compounds known to be effective in treating IBD.
Abstract:
The present invention inter alia relates to gene silencing of the Agr2 gene by short interfering RNAs. Moreover, in view of the involvement of Agr2 in mucus production, the invention also relates to pharmaceutical compositions useful as medicaments in methods for the prevention, amelioration or treatment of medical conditions associated with mucus hyperproduction / hypersecretion, particularly in the respiratory tract. Novel siRNAs which are useful in the above methods, and novel pharmaceutical compositions are likewise provided. The invention further relates to screening methods for additional siRNAs capable of silencing the expression of the Agr2 gene.